NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients

TARRYTOWN, N.Y., March 30, 2021 /PRNewswire/ -- Protocol W trial data confirm results from PANORAMA trial showing EYLEA significantly reduced vision-threatening complications and improved anatomic measures of diabetic retinopathy Although patients' overall vision was similar in the EYLEA...

from PR Newswire: https://ift.tt/2PnRU8b